Beclin 1-defective leukemia cells were more sensitive to necroptotic stimuli in vitro and in vivo with increased MLKL oligomerization, suggesting that Beclin 1 might be a good target for the treatment of leukemia patients. This evidence concerns the gene MLKL and leukemia.